Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

Linden Thomson, senior fund manager at Candriam, notes that weight-loss drugs have become the driver of healthcare investing.

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Novo Nordisk’s Wegovy and Ozempic, which respectively target weight loss and diabetes, were added to the Medicare negotiation ... s opportunity to beat Eli Lilly’s Zepbound, which was approved ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli ... Zepbound for obesity. In the past three months, shares of Novo Nordisk and ...

About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...

How might Medicare price negotiations impact Novo Nordisk's battle in the marketplace with Eli Lilly? Lilly's type 2 diabetes drug Mounjaro and obesity drug Zepbound aren't eligible for Medicare ...